{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:40:15Z","timestamp":1717580415736},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 \u00d7 109\/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.240","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"240-243","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"2014","author":[{"given":"David T.","family":"Yeung","sequence":"first","affiliation":[{"name":"Department of Haematology and Molecular Pathology, SA Pathology, and Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, SA, Australia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111703253081600_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","article-title":"Which TKI? An embarrassment of riches for chronic myeloid leukemia patients","volume":"2013","author":"Hughes","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111703253081600_B2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/asheducation-2013.1.184","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?","volume":"2013","author":"Sweet","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2019111703253081600_B3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2019111703253081600_B4","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology Chronic Myelogenous Leukemia, Version 2.2014 Accessed January 2, 2014 Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"issue":"8","key":"2019111703253081600_B5","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111703253081600_B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111703253081600_B7","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1007\/s13277-013-1585-2","article-title":"Early molecular response in chronic myeloid leukemia patients predicts future response status","volume":"35","author":"Kagita","year":"2014","journal-title":"Tumour Biol"},{"issue":"3","key":"2019111703253081600_B8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111703253081600_B9","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","author":"Hanfstein","journal-title":"Leukemia"},{"issue":"9","key":"2019111703253081600_B10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111703253081600_B11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111703253081600_B12","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703253081600_B13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111703253081600_B14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111703253081600_B15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111703253081600_B16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2013-0584-OA","article-title":"Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the rationale and insight for gleevec high-dose therapy study","volume":"138","author":"Akard","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2019111703253081600_B17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2013.9048","article-title":"Predictive value of pretreatment BCR-ABL(IS) transcript level on response to imatinib therapy in Egyptian patients with chronic phase chronic myeloid leukemia (CPCML)","volume":"9","author":"El-Metnawy","year":"2013","journal-title":"Int J Biomed Sci"},{"issue":"25","key":"2019111703253081600_B18","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111703253081600_B19","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2019111703253081600_B20","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111703253081600_B21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.leukres.2013.11.016","article-title":"Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response","volume":"38","author":"O'Dwyer","year":"2014","journal-title":"Leuk Res"},{"issue":"14","key":"2019111703253081600_B22","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703253081600_B23","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study [abstract]","volume":"120","author":"Brummendorf","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703253081600_B24","first-page":"2767","article-title":"Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial [abstract]","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111703253081600_B25","first-page":"451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression: an update of the TIDEL-II trial [abstract]","volume":"118","author":"Yeung","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111703253081600_B26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111703253081600_B27","first-page":"3426","article-title":"BCR-ABLIS expression at diagnosis and after 3 or 6 months of treatment predicts CML response to imatinib therapy [abstract]","volume":"116","author":"Vigneri","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111703253081600_B28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703253081600_B29","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111703253081600_B30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111703253081600_B31","first-page":"95","article-title":"Switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with suboptimal cytogenetic response (CyR) on imatinib: first results of the LASOR trial [abstract]","volume":"22","author":"Cortes","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"35","key":"2019111703253081600_B32","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111703253081600_B33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"7652","key":"2019111703253081600_B34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/240\/1250663\/bep00114000240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/240\/1250663\/bep00114000240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:45:13Z","timestamp":1717577113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/240\/20509\/Prognostic-significance-of-early-molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.240","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}